EAMON DUTTA: Open Payments
NPI 1396822979 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,582 in 120 payments from 19 companies in 2025. Trend: 2023 $2,723 · 2024 $3,139 · 2025 $2,582
Food & beverage: $2,582
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 17 | $494 |
| Neurocrine BioSciences, Inc. | 17 | $372 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $290 |
| ABBVIE INC. | 12 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $180 |
| LivaNova USA, Inc. | 1 | $170 |
| Teva Pharmaceuticals USA, Inc. | 11 | $167 |
| Otsuka America Pharmaceutical, Inc. | 8 | $139 |
| Axsome Therapeutics, Inc. | 5 | $107 |
| Alkermes, Inc. | 4 | $90 |
Products named: SPRAVATO, INGREZZA, CAPLYTA, VRAYLAR, REXULTI, TRINTELLIX, VNS THERAPY SYMMETRY MODEL 8103 GENERATOR, INVEGA SUSTENNA.
Industry payments across GA — which companies pay providers there.
